glp-1 nejm Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

GLP-1 Receptor Agonists #2026Review @NEJM https://www.nejm .org/doi/full/10.1056/NEJMra2500106

21.46

★★★★☆4.8 (126)

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

25.76

★★★★★4.9 (98)

𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀 ⁣ ⁣ Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong

23.12

★★★★★5.0 (157)

In patients with #obesity, incretin-based therapies such as GLP-1 receptor agonists are reported to result in mean weight reductions of approximately 15 to 20% along with additional health benefits, including decreased cardiovascular

24.32

★★★★★4.7 (84)

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

20.00

★★★★★4.9 (203)

nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential

22.98

★★★★★5.0 (176)

Generic Liraglutide — Overlooked but Not Forgotten

25.22

★★★★★4.8 (132)